Beneath the Surface: Diving into JAK inhibitors for alopecia areata, Part 1
Click Here to Manage Email Alerts
Beneath the Surface is a video series in which Joel M. Gelfand, MD, MSCE, Healio Dermatology Chief Medical Editor, discusses hot topics in the field with leading experts.
In this edition, Gelfand, who is also the James J. Leyden Professor of Clinical Investigation and professor of dermatology and epidemiology at University of Pennsylvania’s Perelman School of Medicine, discusses the efficacy of Janus kinase (JAK) inhibitors for the treatment of alopecia areata with Brett King, MD, PhD, associate professor of dermatology at Yale University School of Medicine and a member of Healio Dermatology’s Peer Perspective Board.
The FDA has approved two JAK inhibitors, baricitinib (Olumiant, Eli Lilly/Incyte) and ritlecitinib (Litfulo, Pfizer), for this indication, and approval of deuruxolitinib (Sun Pharma) is expected by the end of 2024.
In this interview, King explains how multi-modality treatment including a JAK inhibitor and oral minoxidil has shown the highest levels of efficacy in not only scalp hair regrowth, but also eyelash and eyebrow regrowth over a year or longer.
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts